Unither Pharmaceuticals celebrates 30 years of innovation and expertise
Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 3Unither Pharmaceuticals years in business. In the company993, Unither Pharmaceuticals began operations by acquiring a the company7-man pharmaceutical plant that produced 3 pharmaceutical forms. Today, the company is a world leader in the manufacture of sterile unit doses, with a production capacity of 5 billion doses and a presence on four continents. This growth is also reflected in rising sales, which should reach 5Unither PharmaceuticalsUnither Pharmaceuticals million euros by 2Unither Pharmaceuticals23.
To view the Multimedia News Release, please click:
https://www.multivu.com/players/uk/9229051-unither-pharmaceuticals-celebrates-30-years-innovation-expertise/
Unither first implemented Blow-Fill-Seal (BFS) technology in 1995, enabling them to manufacture sterile doses of saline solutions, asthma medications, and eye drops. From 1997 onwards, the company developed its international business, first by exporting its products, then by acquiring a factory in the United States in 2013. With the acquisition of Barretos in 2015, Unither gained a foothold in Brazil. Then in 2020, an acquisition in China, in Nanjing, consolidated its global footprint. In 2022, Unither further expanded its activities with the acquisition of a new site specializing in ophthalmology in S?o Paulo. This international development is designed to support its customers' international industrial strategies by getting closer to their target markets.
Since its inception, Unither has been at the forefront of innovation, continuously striving to improve patients' lives. Eric Goupil, President of Unither Pharmaceuticals, reminds the group's vision: "We want to be recognized for making healthcare solutions that improve and simplify patients' lives accessible to as many people as possible. We imagine new ideas, and our enthusiasm and energy enable us to realize them for the benefit of our customers."
Jean-Francois Hilaire, CEO of Unither Pharmaceuticals, looks to the future: "Unither's vocation is to support our customers in their drive for innovation and in their efforts to meet the demands of their markets. With Euroject(R), our recent breakthrough in merging a single-use dose with a needle to create a ready-to-use injection system, illustrates Unither's commitment to simplifying the lives of healthcare practitioners and patients, while keeping costs under control."
About Unither Pharmaceuticals: www.unither-pharma.com/about/who-are-we/
Press contact: [email protected]
Video - https://www.youtube.com/watch?v=lNCXXx_8wTo
Photo - https://mma.prnewswire.com/media/2287080/Unither_Pharmaceuticals.jpg
Logo - https://mma.prnewswire.com/media/1471719/Unither_Pharmaceuticals_Logo.jpg
ข่าวUnither Pharmaceuticals+the companyวันนี้
Unither Pharmaceuticals celebrates 30 years of innovation and expertise
Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 30 years in business. In 1993, Unither Pharmaceuticals began operations by acquiring a 17-man pharmaceutical plant that produced 3 pharmaceutical forms. Today, the company is a world leader in the manufacture of sterile unit doses, with a production capacity of 5 billion doses and a presence on four continents. This growth is also reflected in rising sales, which should reach 500 million
Kaspersky reports 2024 financial results with record revenue
—
Kaspersky today announces its financial results for 2024, throughout which the company show...
RML Secures Shareholder Approval for All AGM 2025 Resolutions, Accelerates Transformation Roadmap
—
RML is moving forward with the restructuring of its eq...
Duck Creek Technologies Appoints General Daniel Hokanson, USA, Ret. to Board of Directors
Duck Creek Technologies Decorated general brings extensive leadership and policy development expertise to board role Duck Creek Technologies , the global intelligent solutions provider defining the future of...
EGCO Group holds the Shareholders' 2025 Annual General Meeting - Approved a second-half dividend of 3.25 baht per share, totaling 6.50 baht per share for the entire year
SPRC hosts 2025 Annual General Meeting of Shareholders, Confirms its Dividend Payment at Baht 0.15 per share
—
Star Petroleum Refining Public Company Limi...
KTC Delighted with New "AA" Rating from TRIS, Strengthening Its Path Toward Sustainable Growth
—
KTC has been upgraded to an "AA" corporate and debt ratin...
Kaspersky Research Sandbox 3.0: more power, less hardware
—
Kaspersky has launched a major update to Kaspersky Research Sandbox, introducing version 3.0 w...
EGCO Group boosts its renewables fleet with acquisition of 251 MW wind and solar farms in the US
—
Electricity Generating Public Company Limited or EGCO G...